header logo image


Page 9«..891011..2030..»

Archive for the ‘Cell Therapy’ Category

Adler Footcare – Stem Cell Therapy – Video

Monday, November 3rd, 2014


Adler Footcare - Stem Cell Therapy
Backed by years of research, thousands of happy patients, and faster healing time is the latest in ethical stem cell treatments for foot pain offered at Adle...

By: Adler Footcare

Continue reading here:
Adler Footcare - Stem Cell Therapy - Video

Read More...

Stem Cell Therapy | stem cell mobilization gcsf – Video

Monday, November 3rd, 2014


Stem Cell Therapy | stem cell mobilization gcsf
http://www.arthritistreatmentcenter.com Another breakthrough in stem cell science and we have lab rats to thank for it next Osteoarthritis in rats responds to stem cell mobilization therapy...

By: Nathan Wei

More:
Stem Cell Therapy | stem cell mobilization gcsf - Video

Read More...

PURTIER LIVE STEM CELL THERAPY – Video

Monday, November 3rd, 2014


PURTIER LIVE STEM CELL THERAPY
PURTIER INTRODUCTION IN CHINESE Please contact Pearly @ +65 9338 9541 / +65 9189 7351 for more details.

By: Purtier30

View original post here:
PURTIER LIVE STEM CELL THERAPY - Video

Read More...

Stem Cell Therapy BACKSTAGE – Video

Monday, November 3rd, 2014


Stem Cell Therapy BACKSTAGE

By:

Read the rest here:
Stem Cell Therapy BACKSTAGE - Video

Read More...

Cell Therapy Blog: Cell Therapy Conferences 2014

Monday, November 3rd, 2014

JANUARY 2014 State of the Industry Briefing at EBD's Biotech Showcase Jan 13. San Francisco, CA EBD's Biotech Showcase: Regenerative Medicine Industry Track Jan 13-15. San Francisco, CA ECI's Conference on Scale-Up and Manufacturing of Cell-Based Therapies Jan 6-9. San Diego, CA International Conference on Cell Therapy for Cardiovascular Disease Jan 22-24. New York, NY Phacilitate's Cell and Gene Therapy Forum Jan 27-29. Washington, DC FEBRUARY 2014 RRY's New York Stem Cell Summit Feb 18. New York, NY STEMSO's International Stem Cell Society Conference Feb 19-22. Freeport, Grand Bahama BMT Tandem Meetings Feb 26-Mar.Grapevine (Dallas), TX MARCH 2014 Danish Stem Cell Symposium Mar 7-8. Hillerd, Denmark ISBioTech Spring Mtg - Cellular Therapies Track Mar 10-12. Washington, DC AAT's Advanced Therapies Summit Mar 12-13. Turin, Italy ISSCR/SBE International Conference on Stem Cell Engineering Mar 16-19. Coronado, CA Congress on Stem Cell and Cell Therapies Mar 2023. Koceli, Turkey FDA and the Changing Paradigm for HCT/P Regulation Mar 24-26. Bethesda, MD BIRAXs' UK-Israel Regenerative Medicine Conference Mar 25-26. Haifa, Israel ARM's RegenMed Investor Day Mar 26. New York, NY. Regenerative Medicine Workshop at Hilton Head Mar 26-29 . Hilton Head, SC Cancer Immunotherapy: A Long-Awaited Reality Mar 27. NYC, NY. FDA Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Public Mar 31. Silver Spring, MD.

APRIL 2014 Select Biosciences' Clinical Translation of Stem Cells Apr 21-22. Palm Springs, AZ ISCT Annual Meeting Apr 23-26. Paris, France GTCBio's Stem Cell Summit Apr 23-25. Boston, MA ARMs Annual Dinner & Legislative Fly-In Apr 28-9. Washington, DC.

MAY 2014 GeneExpression Systems' Stem Cells and Cell Signaling Mtg on Assays to Regenerative Medicine, Tissue Engineering and Therapeutics May 5-6. Waltham-Boston, MA Regenerative Medicine Foundation Symposium May 5-7. San Francisco, CA CHIsAdoptive T Cell Therapy:New Targets and Strategies for Immune Driven Diseases (part of the Tenth Annual PEGS: the essential protein engineering summit) May 7-8. Boston, MA ASGCT - American Society of Gene and Cell Therapy Mtg May 21-24. Washington, DC Terrapinn's World Stem Cells and Regenerative Medicine Congress May 20-22. London, UK JUNE 2014 PDA Europe: Advanced Therapy Medicinal Products Jun 3-4. Madrid, Spain The Orthobiologic Institute's PRP and Regenerative Medicine Symposium Jun 6-7. Los Angeles, CA Israstem Jun 10-11. Ramat, Gan. Israel TERMIS EU Mtg Jun 10-14. Genova, Italy ISSCR - International Society for Stem Cell Research Mtg Jun 18-21. Vancouver, BC, Canada Cell Tracking Symposium June 20. London, ON

BIO International Convention(with BPI BioProcess Theater) Jun 23-26. San Diego, CA ARM Networking Reception @BIO June 24. San Diego, CA OMIC'sCell Science and Stem Cell Research Jun 24-26. Valencia, Spain JULY 2014 The Business of Regenerative Medicine: New Therapies, New Models July 14-16. Toronto, ON Regenerative Medicine Essentials: The Fundamentals to the Future. July 21-25.Winston-Salem, NC

AUGUST 2014 CHI'sCell Therapy Bioproduction (part of the Bioprocessing Summit) Aug 18-22. Boston, MA Rejuvenation Biotechnology: Emerging Regenerative Medicine Solutions for the Diseases of Aging conference Aug 21-23. Santa Clara, CA.

SEPTEMBER 2014 Terrapinn's Stem Cells USA and Regenerative Medicine Congress Sep 15-16. Boston, MA IBC's Cell Therapy Bioprocessing Sep 15-16. Arlington, VA TERMIS Asia Pacific Mtg Sep 24-17. Daegu, S. Korea

OCTOBER 2014 Cancer Immunotherapy 2014 Oct. 6. New York City, NY ARM's Stem Cell Meeting on the Mesa Oct 7-9. La Jolla, CA Fraunhofer Life Science Symposium"Medicinal Stem Cell Products Oct 9-10. Leipzig, Germany Translational Regenerative Medicine Congress Oct 21-22. Leipzig, Germany CCRM-SCN Till and McCulloch Meetings Oct 27-29. Ottawa, ON, Canada OMICS' International Conference and Exhibition on Cell and Gene Therapy Oct 27-29. Las Vegas, NV

NOVEMBER 2014 ISSCR/SSCS Global Controls in Stem Cells Nov 5-7, 2014. Singapore Society for Immunotherapy of Cancer Annual Meeting Nov 6-9. National Harbor, MD International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis Nov 8-10. New Delhi, India IFATS Annual Mtg Nov 13-16. Amsterdam, NL BIT's World Congress of Regenerative Medicine & Stem Cells (RMSC2014) Nov 13-16.Haikou, China Commercial Translation of Regenerative Medicine Nov/Dec ??. London, UK DECEMBER 2014 Cell Therapy Manufacturing Dec 3-4. Brussels, Belgium World Stem Cell Summit Dec 3-5. San Antonio, TX TERMIS Americas Mtg Dec 13-16. Washington, DC If I've missed an event you'd like to see added, please email me at lbuckler [at] celltherapygroup [dot] com.

View post:
Cell Therapy Blog: Cell Therapy Conferences 2014

Read More...

Stem Cell Therapy | stem cells fraud – Video

Friday, October 31st, 2014


Stem Cell Therapy | stem cells fraud
http://www.arthritistreatmentcenter.com Too good to be true. And I was fooled also Japanese stem cell breakthrough, a fraud Reported by Rob Stein in Shots, a prestigious scientific journal...

By: Nathan Wei

Read the original:
Stem Cell Therapy | stem cells fraud - Video

Read More...

Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid …

Friday, October 31st, 2014

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI's stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Originally posted here:
Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid ...

Read More...

Medical groups call for major stem cell investment from public, private sector

Wednesday, October 29th, 2014

OTTAWA - A coalition of Canadian stem cell advocates, researchers and charities is calling for $1.5 billion in private and public funding for stem cell therapy over the next 10 years.

The coalition's action plan is aimed at cementing Canada's reputation as a stem cell leader, one that uses stem cell science to reduce suffering and death from cardiovascular diseases, cancer, diabetes, vision loss, spinal cord injuries and other conditions.

James Price, the president and CEO of the Canadian Stem Cell Foundation, says the action plan could help millions of people with new, life-changing therapies.

The action plan's call for funding includes a $50 million scaled annual average commitment by the federal government.

The Centre for Commercialization of Regenerative Medicine estimates the action plan could also create more than 12,000 jobs due to the growth of existing companies and the development of new enterprises aimed at global markets.

Read more:
Medical groups call for major stem cell investment from public, private sector

Read More...

Copy of PhytoScience Philippines Celeb Share good effect of Stem Cell Therapy – Video

Wednesday, October 29th, 2014


Copy of PhytoScience Philippines Celeb Share good effect of Stem Cell Therapy
PHYTOSCIENCE DOUBLE STEM CELL removes the apperance of age lines and restore smoth, radiant, youthful looking skin! LOOK YOUNGER REDUCE THE LOOK OF WRINKLES LINES ...

By: Emmanuel Villamor Jr

Link:
Copy of PhytoScience Philippines Celeb Share good effect of Stem Cell Therapy - Video

Read More...

The Miracle of Stem Cell Therapy at Adler Footcare Regenerates Cells, Heals Foot Pain

Wednesday, October 29th, 2014

New York, New York (PRWEB) October 29, 2014

Stem cell therapy is the future of foot pain treatment. New York podiatrists at Adler Footcare are using ethical stem cell treatments for foot problems to help speed healing, minimize pain, and reduce swelling.

Stem cells are cells that havent quite yet determined their role in the body. This gives them the ability to turn into anything. The treatment is being used for problems causing foot pain, such as Achilles tendonitis, plantar fasciitis, and arthritis of the first toe joint. Stem cells help regenerate new cartilage and helps tissue heal much quicker.

"Stem cells turn into everything," said Dr. Jeffrey Adler, Medical/Surgical Director & Owner of Adler Footcare. "So basically, if the damage is due to cartilage, they turn into cartilage. If the damage is due to soft tissue, they turn into soft tissue. Its the Swiss army knife of treatments."

The stem cells are not live embryos, but instead are generated from the placenta and ethically obtained during the C-sections of live births. The women who the cells are taken from are screened and tested for any communicable diseases beforehand.

Stem cell therapy uses a minimally invasive technique to inject the cells directly into the area where the patient is feeling the foot pain. Fluoroscopy is used to determine the exact position for injection. When stem cell therapy is used healing occurs twice as fast. As the tissues are regenerated and the swelling is minimized, the patient is able to experience more range of motion, less post-operative pain, and less inflammation.

The New York podiatrists at Adler Footcare have been using stem cell therapy for 2 years. They continue to stay up-to-date on the process and have seen only positive results.

To learn more about stem cell treatment for foot pain, contact a New York podiatrist at Adler Footcare.

About Dr. Jeffrey L. Adler

Dr. Jeffrey L. Adler, Medical/Surgical Director and Owner of Adler Footcare of Greater New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Go here to see the original:
The Miracle of Stem Cell Therapy at Adler Footcare Regenerates Cells, Heals Foot Pain

Read More...

Gene therapy, stem cell therapy trials underway

Wednesday, October 29th, 2014

Stem cells and gene hold promising treatment options for Parkinson's, mandate doctors across the globe, including from Mumbai. Eleven trials to test stem cell and gene therapy for treating Parkinson's are underway currently of which the one in Mumbai had to be put on hold due to regulatory hurdles.

Currently, neuro-augmentative therapies such as usage of drugs or deep brain stimulation (DBS) are being used to treat Parkinson's disorder. "The future holds hope for neuro-restorative therapies like that of stem cells or gene infusion in the Parkinson's disorder treatment. It involves restoration of brain function to normal. In the next five to seven years, this may pave the way for future," said Dr Paresh Doshi, neurologist at Jaslok Hospital, Peddar Road in Mumbai.

Regulatory hurdles and resource constraints though have led to these trials being held up in Mumbai. Dr Doshi said that trials of Duodopa therapy which involves infusion of an active ingredient gel called Levodopa in the intestines has been kept on hold at the moment at privately-run Jaslok Hospital due to regulatory hurdles. The hospital was the only centre in entire South East Asia to have been running the trial.

"Levodopa gets converted into dopamine in the body. Normal levels of dopamine control Parkinsons disorder," said Dr Doshi.

Trials to infuse stem cells from the patient's body in the patient itself had been underway in small group of patients in India, but due to inability to recruit more patients, the trial was stopped. "We could only recruit four patients for two years. However, a similar trial is underway in China and another trial which explores adipose tissue stem cells in treating Parkinson's disease is underway in South Africa," said Dr Doshi.

In January this year, medical journal The Lancet reported that after sixteen years of trials, gene therapy is showing promising results in humans. "Three genes that promote the formation of dopamine generating cells in the brain were injected in the brain bound with a viral vector in fifteen patients. The genes are intended to boost the production of dopamine, a chemical that becomes deficient in patients withParkinson's," said The Lancet report.

View original post here:
Gene therapy, stem cell therapy trials underway

Read More...

My Pet World: Stem cell treatments show promise for some feline health issues

Tuesday, October 28th, 2014

Q: You recently wrote about stem cell research, and I understand that stem cell therapy is being used to treat inflammatory bowel disease in cats. Do you have more details?

A: The Winn Feline Foundation has funded the research of Dr. Craig Webb and Dr. Tracy Webb of Colorado State University College of Veterinary Medicine to study the use of stem cells to treat inflammatory bowel disease in cats. Early results are promising.

Stem cell research in cats doesn't stop there. Dr. Glenn Olah, president of the Winn Feline Foundation, notes that Winn also funded stem cell studies to treat feline asthma and kidney disease. Results are hopeful, but it's simply too early to offer definitive answers.

"In some ways, stem cell studies in pets are ahead of (those in) people."

Q: About a month ago, I adopted a beautiful Burmese after she romanced me at the shelter. Once we got home, she wanted nothing to do with me. It's not that she isn't friendly. She loves my son and even sleeps with him. When I get up early to feed her, she stays away until I've left the room. My son suggested that the cat harbors resentment toward me because I took her from her cat friends. What can do to improve the situation?

A: "The good news is that it's very unlikely the cat harbors any resentment," said Winn Feline board member and feline veterinarian Dr. Drew Weigner, of Atlanta. "The bad news for you -- but good news for the cat and your son -- is that they developed a fast friendship.

Here are tips that might help the cat warm up to you:

Sit on the floor in an empty room with her. Close the door, but provide an empty box or two for the cat to hop into. Then, simply watch TV, or read a children's story out loud. Cats sometimes like that soft sing-song voice we tend to use when reading children's stories.

Wait until the cat comes to you. It may take several days, but eventually curiosity will out.

Next, take over feeding the cat, even if she waits for you to leave the room to eat.

Follow this link:
My Pet World: Stem cell treatments show promise for some feline health issues

Read More...

Lyme Disease and Embryonic Stem Cell Therapy Testimonial – Video

Sunday, October 26th, 2014


Lyme Disease and Embryonic Stem Cell Therapy Testimonial
Kim gives a testimonial after 3 months of having followed the Stemaid Lyme Disease Protocol.

By: stemaid

Read the original post:
Lyme Disease and Embryonic Stem Cell Therapy Testimonial - Video

Read More...

Stem Cell Therapy Help Buddy the Beagle – Video

Sunday, October 26th, 2014


Stem Cell Therapy Help Buddy the Beagle
Buddy the beagle wasn #39;t able to walk when he first arrived at the University of Minnesota Veterinary Medical Center. With the help of the Veterinary Medical ...

By: UMN Health

See more here:
Stem Cell Therapy Help Buddy the Beagle - Video

Read More...

Tuffy stem cell therapy patient – Video

Sunday, October 26th, 2014


Tuffy stem cell therapy patient
Tuffy 2 months after he received Stem Cell Therapy here. He is running around now like nothing happened. I can not believe he was hit by a car and broke his back in 2 places just 2 months ago.

By: Noel Berger

See the original post:
Tuffy stem cell therapy patient - Video

Read More...

Scleroderma patients seek experimental U.S. stem cell therapy

Sunday, October 26th, 2014

CTVNews.ca Staff Published Saturday, October 25, 2014 10:30PM EDT Last Updated Saturday, October 25, 2014 11:46PM EDT

An estimated 16,000 Canadians live with scleroderma, an incurable autoimmune disorder which causes the body to produce too much collagen, resulting in a hardening of the skin and tissue. There is no cure for the scleroderma, but some patients in Canada are now seeking a costly and experimental stem cell therapy in the U.S.

A little over a year ago, Mike Berry of Kingston, Ont., started having trouble breathing. It was the first sign of scleroderma.

Berry, 42, suffers from the systemic version of scleroderma, which attacks his internal organs. His lungs have been scarred by the disorder, with his lung capacity dropping to 41 per cent in just nine months. His disease may ultimately be fatal.

He described to CTV News how scleroderma has impacted his day-to-day life.

"I'm unable to work any longer; it affects me and everything now," he said. "It's hard to walk fast; I can't walk and talk."

Drugs to treat his scleroderma haven't worked, so now Berry is trying to fundraise more than $150,000 for an experimental U.S. stem cell treatment called Autologous Hematopoietic Stem Cell Transplantation (HSCT), in the hopes that it will save his life.

"It would give me as second chance, I guess I just have a lot to fight for," he said.

Pioneered by Dr. Richard Burt at Northwestern Memorial Hospital in Chicago, patients receiving HSCT are administered stem cells intravenously.

During the treatment, the patient's stem cells are harvested, and then the patient's over-active immune system is destroyed with powerful chemotherapy drugs. Doctors then re-program the patient's immune system with the harvested stem cells, in the hopes that the cells will "reset" the patient's immune system and stop scleroderma.

Read more here:
Scleroderma patients seek experimental U.S. stem cell therapy

Read More...

StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Wednesday, October 22nd, 2014

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

More here:
StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Read More...

Dr Charles Krome Stem Cell Therapy – Video

Sunday, October 19th, 2014


Dr Charles Krome Stem Cell Therapy
This video is about Dr Charles Krome Stem Cell Therapy.

By: John lore

Here is the original post:
Dr Charles Krome Stem Cell Therapy - Video

Read More...

Shannon Layne, DVM and VCA Dunmore Animal Hospital Now Offer Stem Cell Therapy to Pet Patients in Pain

Friday, October 17th, 2014

Dunmore, Pennsylvania (PRWEB) October 17, 2014

VCA Dunmore Animal Hospital is proud to announce the addition of Shannon Layne, DVM and her interest in stem cell therapy to their team. Credentialed in Regenerative Cell Therapy with Vet-Stem since January of 2011, Dr. Layne has proudly been treating pets with osteoarthritis and ligament injuries in north-east Pennsylvania with stem cell therapy for the last four years.

Dr. Layne graduated from North Carolina State University, College of Veterinary Medicine in 2010 and has taken a special interest in Regenerative Veterinary Medicine and stem cell therapy since. In contrast to widely used drug therapies for pain management, cell-based therapies (like stem cell therapy) can promote healing, reduce inflammation, and decrease pain. Dr Layne also offers traditional Chinese veterinary medicine including acupuncture and Chinese herbs if clients are interested in a more holistic approach.

Stem cells are regenerative cells that can differentiate into many tissue types (reducing pain and inflammation) thus helping to restore range of motion and regenerate tendon, ligament and joint tissues (Vet-Stem.com/science). In a study using Vet-Stem Regenerative Cell Therapy on dogs with osteoarthritis of the hip joint it was found that regenerative cell therapy (adipose-derived stem cells) decreases patient discomfort and increases patient functional ability.

Once Dr. Layne has identified a patient as a good candidate for stem cell therapy the procedure begins with a fatty tissue collection from the patient. The tissue sample is sent overnight to Vet-Stems lab in California for processing. Once processed the stem cells are extracted and fresh, injectable doses of the patients stem cells are sent overnight, back to Dr. Layne at VCA Dunmore Animal Hospital. Within 48hrs of collecting a fat sample from a patient Dr. Layne is able to inject stem cells into (arthritic or injured) affected areas and regeneration and healing can begin.

At VCA Dunmore Animal Hospital Dr. Layne will be practicing in an 8,800 square foot, state of the art facility that includes two extensive surgery suites. For more information on VCA Dunmore Animal Hospital please visit their website at http://www.vcahospitals.com/dunmore.

About Vet-Stem, Inc.

Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells.

For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.

Link:
Shannon Layne, DVM and VCA Dunmore Animal Hospital Now Offer Stem Cell Therapy to Pet Patients in Pain

Read More...

Embryonic Stem Cell Therapy Shows Long-Term Effectiveness, Safety

Thursday, October 16th, 2014

TUESDAY, Oct. 14, 2014 (HealthDay News) -- A new study is the first to show the long-term safety of embryonic stem cell transplants to treat human disease.

The research involved 18 people who received the transplants to treat forms of macular degeneration, a leading cause of vision loss.

The transplants, which restored some sight in more than half of the patients, appeared safe up to three years after the procedure.

The study, funded by a U.S.-based company called Advanced Cell Technology, was published Oct. 14 in The Lancet.

"Embryonic stem cells have the potential to become any cell type in the body, but transplantation has been complicated by problems," lead author Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, said in a journal news release. Those problems include the rejection of the transplanted cells by the patient's immune system, as well as the danger that the cells might spur certain types of cancers called teratomas.

A teratoma is a type of cancer that occurs when stem cells develop into multiple types of cells and form incompatible tissues that can include teeth and hair.

As Lanza explained, because of these issues, scientists interested in embryonic stem cell therapy have tended to focused on sites in the body that typically do not produce a strong immune response. The eye is one such spot.

In the new study, human embryonic stem cells were first prompted to develop into eye cells called retinal pigment epithelial cells. They were then transplanted into nine people with Stargardt's macular dystrophy, and another nine with dry atrophic age-related macular degeneration.

Patient outcomes were tracked for up to three years after transplant. No signs of either cancer-like cell growth (hyperproliferation) or immune system rejection were found in any of the treated eyes after a median follow-up of 22 months, and the only adverse events were linked not to the transplanted cells, but to the eye surgery or immune system suppression needed for the transplant.

Overall, 10 of the 18 patients said they had significant improvements in their vision, and this improvement was only seen in the eyes that had received the stem cell treatment.

Read more here:
Embryonic Stem Cell Therapy Shows Long-Term Effectiveness, Safety

Read More...

Page 9«..891011..2030..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick